BARD1 Life Sciences
Follow
Get notifications in MyBN when activity occurs.
BARD1 Life Sciences Ltd (BD1) is an Australian life sciences company focused on developing and commercializing non-invasive diagnostic tests for early detection of cancer.
BARD1's proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage BARD1 autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer.
BARD1's proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage BARD1 autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer.
Contact Details
Unit 202, Level 2, 39 Mends St, SOUTH PERTH WA 6151
08 9381 9550
Lists and Charts
Public Companies - Industrial WA list sponsored by
Share Price
Closing price for the last 90 trading days
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 797th |  | BARD1 Life Sciences | $539k |
| 801st | | Living Cell Technologies | $498k |
| 802nd | | Oventus Medical | $491k |
| 804th | | K-TIG | $478k |
| 805th | | Bentley Capital | $475k |
1216 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Total Shareholder Return as at 29/01/21
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 350th | Bentley Capital | 135% | -2% |
| 436th | K-TIG | 100% | 25% |
| 1281st | Living Cell Technologies | -6% | -19% |
| 1708th | BARD1 Life Sciences | -43% | -3% |
| 1728th | Oventus Medical | -45% |
1753 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Article Timeline
Company Activity
| NEWS: Tagged in BARD1 soars on cancer tech update | 15 Feb 2021 |
| NEWS: Tagged in Board Moves January 11-15, 2021 | 16 Jan 2021 |
| NEWS: Tagged in Board Moves November 25, 2020 | 25 Nov 2020 |
| REMUNERATION UPDATE: Irmgard Irminger-Finger, Executive Director | 02 Nov 2020 |
| REMUNERATION UPDATE: Peter Gunzburg, Executive Chair, Managing Director | 02 Nov 2020 |
| REMUNERATION UPDATE: Philip Powell, Non-Executive Director | 02 Nov 2020 |
| REMUNERATION UPDATE: Peter Gunzburg, Executive Chair, Managing Director | 24 Aug 2020 |
| REMUNERATION UPDATE: Irmgard Irminger-Finger, Executive Director | 24 Aug 2020 |
| REMUNERATION UPDATE: Leearne Hinch, Chief Executive | 24 Aug 2020 |
| NEW ROLE: Irmgard Irminger-Finger, Chief Scientific Officer | 17 Aug 2020 |
